EMVision Medical Devices Beheer

Beheer criteriumcontroles 3/4

De CEO EMVision Medical Devices is Scott Kirkland, benoemd in Jul2023, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 557.06K, bestaande uit 56.5% salaris en 43.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5% van de aandelen van het bedrijf, ter waarde A$ 8.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.4 jaar.

Belangrijke informatie

Scott Kirkland

Algemeen directeur

AU$557.1k

Totale compensatie

Percentage CEO-salaris	56.5%
Dienstverband CEO	1.3yrs
Eigendom CEO	5.0%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

Nov 09

Recent updates

EMVision Medical Devices (ASX:EMV) Is Using Debt Safely

Aug 28

Is EMVision Medical Devices (ASX:EMV) A Risky Investment?

Nov 21

Here's Why We're Not At All Concerned With EMVision Medical Devices' (ASX:EMV) Cash Burn Situation

Apr 24

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

Nov 09

We're Not Very Worried About EMVision Medical Devices' (ASX:EMV) Cash Burn Rate

Oct 04

Companies Like EMvision Medical Devices (ASX:EMV) Are In A Position To Invest In Growth

Jun 17

Here's Why We're Not Too Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Situation

Feb 22

Investors Who Bought EMvision Medical Devices (ASX:EMV) Shares A Year Ago Are Now Up 319%

Dec 20

We Think EMvision Medical Devices (ASX:EMV) Can Afford To Drive Business Growth

Nov 24

Analyse CEO-vergoeding

Hoe is Scott Kirkland's beloning veranderd ten opzichte van EMVision Medical Devices's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$557k	AU$315k	-AU$3m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$3m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$285k	AU$258k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	AU$270k	AU$245k	-AU$6m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$7m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$262k	AU$240k	-AU$8m
Mar 31 2021	n/a	n/a	-AU$7m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$224k	AU$205k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$213k	AU$150k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	AU$45k	AU$41k	-AU$2m

Compensatie versus markt: De totale vergoeding ($USD 362.22K ) Scott } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 298.55K ).

Compensatie versus inkomsten: De vergoeding van Scott is gestegen terwijl het bedrijf verliesgevend is.

CEO

Scott Kirkland

1.3yrs

Tenure

AU$557,063

Compensatie

Mr. Scott Kirkland has been an Executive Director of EMvision Medical Devices Limited since July 11, 2017 and serves as its Chief Executive Officer and Managing Director since July 01, 2023. Mr. Kirkland h...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Kirkland	CEO, MD & Executive Director	1.3yrs	AU$557.06k	5% A$ 8.1m
Emma Waldon	CFO & Company Secretary	7.3yrs	geen gegevens	1.36% A$ 2.2m
Forough Khandan	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	3.9yrs	geen gegevens	1.22% A$ 2.0m
Robert Tiller	Head of Design	3.8yrs	geen gegevens	geen gegevens
Konstanty Bialkowski	Head of Tech Development	no data	geen gegevens	geen gegevens
Christian Wight	Head of Regulatory Affairs	1.6yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van EMV wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Kirkland	CEO, MD & Executive Director	7.3yrs	AU$557.06k	5% A$ 8.1m
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	5.4yrs	geen gegevens	1.22% A$ 2.0m
Geoffrey Donnan	Ex-Officio Member of Clinical Advisory Board	2.7yrs	geen gegevens	geen gegevens
Philip Dubois	Independent Non-Executive Director	4.2yrs	AU$55.50k	0.056% A$ 89.5k
John Keep	Non-Executive Chairman	6.7yrs	AU$105.45k	2.42% A$ 3.9m
Geoffrey Richard Pocock	Non-Executive Director	6.7yrs	AU$55.50k	1.0% A$ 1.6m
Tony Keane	Independent Non-Executive Director	6.4yrs	AU$51.83k	0.70% A$ 1.1m
Michael O'Sullivan	Member of Clinical Advisory Board	5.4yrs	geen gegevens	geen gegevens
David Cook	Member of Clinical Advisory Board	5.4yrs	geen gegevens	geen gegevens
James Walsham	Member of Clinical Advisory Board	5.4yrs	geen gegevens	geen gegevens
Ken Mitchell	Member of Clinical Advisory Board	5.4yrs	geen gegevens	geen gegevens
Stephen Davis	Ex-Officio Member of Clinical Advisory Board	2.7yrs	geen gegevens	geen gegevens

5.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van EMV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

EMVision Medical Devices Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Less than half of directors are independent

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Less than half of directors are independent

Recent updates

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

EMVision Medical Devices (ASX:EMV) Is Using Debt Safely

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.05 loss in FY 2023)

EMVision Unveils Backpack-Sized Brain Scanner to Empower First Responders

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

EMVision Medical Devices Ltd has filed a Follow-on Equity Offering in the amount of AUD 15.281174 million.

EMVision Medical Devices Ltd has completed a Follow-on Equity Offering in the amount of AUD 15.281174 million.

EMVision Medical Devices Ltd announced that it expects to receive AUD 15.281174 million in funding from Keysight Technologies, Inc.

Is EMVision Medical Devices (ASX:EMV) A Risky Investment?

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.081 loss in FY 2022)

New minor risk - Financial data availability

Emvision Medical Devices Limited Receives $1.75 Million Manufacturing Grant Award

Here's Why We're Not At All Concerned With EMVision Medical Devices' (ASX:EMV) Cash Burn Situation

No longer forecast to breakeven

EMVision Medical Devices Limited Provides an Update on Its Clinical Trial and Achievement of an Important Technical Development Milestone

EMVision Commences Clinical Trial

Less than half of directors are independent

EMVision Medical Devices Ltd Announces its Portable Brain Scanner Delivered to First Clinical Site

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

We're Not Very Worried About EMVision Medical Devices' (ASX:EMV) Cash Burn Rate

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.081 loss per share (vs AU$0.12 loss in FY 2021)

Companies Like EMvision Medical Devices (ASX:EMV) Are In A Position To Invest In Growth

Less than half of directors are independent

EMvision Medical Devices Limited Announces Clinical Advisory Board Appointments

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

CEO, MD & Director exercised options to buy AU$2.3m worth of stock.

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

Full year 2021 earnings released: AU$0.12 loss per share (vs AU$0.057 loss in FY 2020)

EMvision Medical Devices Limited provides an update on the build of its First Gen device

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

Medical Devices Limited Announces Australian Stroke Alliance in Collaboration with EMVision Wins Stage 2 MRFF Bid

Here's Why We're Not Too Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Situation

New 90-day low: AU$2.70

EMvision Medical Devices Limited Announces FDA Provides De Novo Guidance

New 90-day low: AU$2.71

EMvision Medical Devices Limited Submits 513(G) Request for Information to the United States Food and Drug Administration

Investors Who Bought EMvision Medical Devices (ASX:EMV) Shares A Year Ago Are Now Up 319%

EMVision Medical Devices Limited Appoints Stuart Crozier as Chief Scientific Officer

We Think EMvision Medical Devices (ASX:EMV) Can Afford To Drive Business Growth

New 90-day high: AU$3.01

EMvision Medical Devices Limited Announces Board Changes

New 90-day high - AU$2.35

Full year earnings released - AU$0.056 loss per share

New 90-day high - AU$1.90

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur